Funder: National Institutes of Health

Due Dates: June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision) | October 5, 2025 (New) | November 5, 2025 (Renewal/Resubmission/Revision) | February 5, 2026 (New) | March 5, 2026 (Renewal/Resubmission/Revision) | June 5, 2026 (New) | July 5, 2026 (Renewal/Resubmission/Revision)

Funding Amounts: Up to $350,000 direct costs per year, for up to 5 years (R01 mechanism; actual needs should be justified in the application).

Summary: Supports secondary analysis and integration of existing datasets to elucidate cancer risk and related outcomes, including risk prediction, survival, and treatment response.

Key Information: Clinical trials are not allowed; up to 10% of the budget may be used for new data generation solely for validation of key findings.